Company Overview
Company Type: Private Company
Website: www.qvella.com
Number of Employees: -
Year Founded: -
Total Amount Raised (CAD mm)†: 50.42
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Qvella Corporation, a Molecular Diagnostics company, offers sample preparation and detection technologies to clinical microbiology. The company is based in Toronto, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Alavie, Tino
Founder and Chief Executive Officer
Fricker, Michael
Chief Financial Officer

Key Board Members
Name
Title
Cassidy, James Parker
Director


Primary Industry Classification
Biotechnology


Primary Office Location
Toronto, ON | Canada

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
bioMérieux S.A. (ENXTPA:BIM)
Dec-04-2017
Unknown
-
Series B
-
Sands Capital Management, LLC
Dec-04-2017
Unknown
-
Series B
-
Hatteras Venture Advisors VI, LLC
Jun-23-2015
Unknown
-
Series A
Myla Lai-Goldman
RA Capital Management, L.P.
Jun-23-2015
Unknown
-
Series A
-
Sands Capital Ventures, LLC
Jun-23-2015
Minority
-
Series A
-

Prior Investors
The Health Technology Exchange


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
NOVX Systems Inc.
NOVX Systems Inc. develops and manufactures point-of-collection drug screening devices for the addiction treatment centers, drug courts, third party administrators, and school administrators. Its products include iMDx Analyzer that tests urine for drugs of abuse and adulterants; ezVu, a Web-based application that automates the chain of custody; PatientVu, a software platform designed to manage electronic healthcare records; PatientVu Pain, a multi-disciplinary Web-based EMR designed to enable the clients to manage their clinics and patients; and ClientVu, a software platform, which is designed to manage the electronic case records. The company was founded in 2001 and is based in Richmond Hill, Canada. As of March 6, 2014, NOVX Systems Inc. operates as a subsidiary of Qvella Corporation.

United States and Canada
Health Care Equipment
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Dec-04-2017
Dec-04-2017
Private Placement
Target
Qvella Corporation
Whitecap Venture Partners,RA Capital Management, L.P.,Hatteras Venture Advisors VI, LLC,Sands Capital Management, LLC,bioMérieux S.A. (ENXTPA:BIM)

19.67
Jun-23-2015
Jun-23-2015
Private Placement
Target
Qvella Corporation
Whitecap Venture Partners,RA Capital Management, L.P.,Hatteras Venture Advisors VI, LLC,Sands Capital Ventures, LLC Buyer Funds:Whitecap III LP

20.00
Mar-6-2014
Mar-6-2014
Merger/Acquisition
Buyer
NOVX Systems Inc.
Qvella Corporation
Presidio Partners,Celtic House Venture Partners Inc.
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Apr-22-2022
Product-Related Announcements
Qvella Corporation Announces FAST System and FAST-PBC Prep Cartridge Get CE Marked and FDA Listed for In Vitro Diagnostic Use
Dec-04-2017
Private Placements
Qvella Corporation announced that it has received CAD 25 million in funding from RA Capital Management, LLC, Whitecap Venture Partners, Hatteras Venture Partners, Sands Capital Management, LLC, bioMérieux S.A.
Jun-23-2015
Private Placements
Qvella Corporation announced that it has received $20 million in funding from Whitecap Venture Partners and other investors.
Mar-06-2014
M&A Transaction Closings
Qvella Corporation acquired NOVX Systems Inc.

Competitors
Abbott Molecular Inc., Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), aprimeo diagnostics GmbH & Co. KG, bioMérieux S.A. (ENXTPA:BIM), Curetis N.V., Danaher Corporation (NYSE:DHR), GenMark Diagnostics, Inc., Hologic, Inc. (NasdaqGS:HOLX), Luminex Corporation, Mobidiag Oy, Qiagen N.V. (NYSE:QGEN), Randox Laboratories Ltd., Robert Bosch GmbH, Roche Diagnostics GmbH, Seegene, Inc. (KOSDAQ:A096530), Siemens Aktiengesellschaft (XTRA:SIE), T2 Biosystems, Inc. (NasdaqCM:TTOO)


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 07:05 PM
Qvella Corporation
Qvella Corp
Reports
35
GlobalData

Jun 16, 2023 01:00 AM
Qvella Corporation
Qvella Corp
Reports
33
GlobalData

Mar 16, 2023 02:17 AM
Qvella Corporation
Qvella Corp
Reports
33
GlobalData

Dec 14, 2022 07:29 PM
Qvella Corporation
Qvella Corp
Reports
33
GlobalData

Sep 16, 2022 05:05 AM
Qvella Corporation
Qvella Corp
Reports
33
GlobalData

Jun 15, 2022 01:08 AM
Qvella Corporation
Qvella Corp
Reports
33
GlobalData

Mar 14, 2022 02:34 AM
Qvella Corporation
Qvella Corp
Reports
32
GlobalData

Dec 16, 2021 01:41 AM
Qvella Corporation
Qvella Corp
Reports
35
GlobalData

Dec 15, 2021 08:39 AM
Qvella Corporation
Qvella Corp - Medical Equipment - Deals and Alliances Profile
Reports
21
GlobalData

Sep 27, 2021 09:35 AM
Qvella Corporation
Qvella Corp - Medical Equipment - Deals and Alliances Profile
Reports
19


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Cassidy, James Parker
Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Alavie, Tino
Founder and Chief Executive Officer
-
-
alavie@novxsystems.com
Fricker, Michael
Chief Financial Officer
416-324-5419
-
michael@whitecastle.ca
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
